Pmgc Holdings Inc. income statement
In fiscal 2025, Pmgc Holdings Inc. reported revenue of $590,084, down 65.5% on the year before and net income of −$7.7m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2022Dec 2022 | 2023Dec 2023 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|
| Revenue | 1 | 2 | 1 | 3 |
| Cost of revenue | 0 | 2 | 0 | 2 |
| Gross profit | 0 | 1 | 0 | 1 |
| Research and development | 0 | 0 | 0 | 0 |
| Selling and marketing | 0 | 1 | — | — |
| General and administrative | 1 | 0 | 2 | 5 |
| Interest expense | 0 | 0 | 0 | 1 |
| Income before tax | — | — | −8 | — |
| Income tax | — | — | 0 | — |
| Net income | −2 | −4 | −8 | −13 |
| Diluted EPS | −$226.80 | −$2.40 | — | — |
| Diluted shares (average) | — | — | — | — |
| Quarter | 2023 Q4Dec 2023 | 2024 Q1Mar 2024 | 2024 Q2Jun 2024 | 2024 Q3Sept 2024 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 |
| Cost of revenue | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling and marketing | −316 | 0 | 1 | — | — | — | — | — |
| General and administrative | −1 | 0 | 0 | 0 | 1 | 1 | 1 | 2 |
| Operating income | — | −2 | −1 | −1 | −2 | — | — | — |
| Interest expense | −13 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Net income | −1 | −1 | −1 | −2 | −3 | −3 | −5 | −3 |
| Diluted EPS | −$0.49 | −$0.28 | −$0.28 | −$0.07 | — | — | — | — |
| EBITDA | — | −2 | −1 | −1 | −2 | — | — | — |
Compare with peers
- Vistagen Therapeutics, Inc. income statement
- Korro Bio, Inc. income statement
- Collplant Biotechnologies Ltd income statement
- Upstream Bio, Inc. income statement
- Xenetic Biosciences, Inc. income statement
Head to head: ELAB vs VTGNELAB vs KRROCLGN vs ELAB
More: Biotechnology stocks compared, Health Care sector, rankings of US companies